Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging.
Article in Radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Mehran BaboliFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0002-0028-0618
Fuyixue WangFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0001-8975-2775
Zijing DongFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).
Jorg DietrichFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0001-8291-0136
Erik J UhlmannFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0003-1432-4754
Tracy T BatchelorFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0001-7568-6607
Daniel P CahillFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0003-2552-6546
Ovidiu C AndronesiFrom the Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, 149 Thirteenth St, Ste 2301, Charlestown, MA 02129 (M.B., F.W., Z.D., O.C.A.); Harvard Medical School, Boston, Mass (M.B., F.W., Z.D., J.D., E.J.U., T.T.B., D.P.C., O.C.A.); Department of Neurology, Papas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Mass (J.D.); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass (E.J.U.); Department of Neurology, Brigham and Women's Hospital, Boston, Mass (T.T.B.); Dana Farber Cancer Institute, Boston, Mass (T.T.B.); and Department of Neurosurgery, Massachusetts General Hospital, Boston, Mass (D.P.C.).ORCID 0000-0002-7412-0641
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5M
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH gliomaR01CA211080 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Ovidiu C Andronesi · 2017 to 2026
$5.4M
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patientsR01CA255479 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ANDRONESI, OVIDIU C · 2021 to 2025
$3.0M
Advancing fMRI Acquisition through Dissemination of EPTI- An Efficient Distortion-Free Multi-Contrast Imaging TechnologyU24NS129893 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Fuyixue Wang · 2023 to 2026
$2.6M
Imaging brain-wide subarachnoid and perivascular cerebrospinal fluid flow in aging and Alzheimer's diseaseK99AG083056 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DONG, ZIJING · 2023 to 2024
backgroundMR spectroscopic imaging (MRSI) can be used to quantify an extended brain metabolic profile but is confounded by changes in tissue water levels due to disease. PURPOSE: To develop a fast absolute quantification method for metabolite concentrations combining whole-brain MRSI with echo-planar time-resolved imaging (EPTI) relaxometry in individuals with glioma and healthy individuals. MATERIALS AND
methodsIn this prospective study performed from August 2022 to August 2023, using internal water as concentration reference, the MRSI-EPTI quantification method was compared with the conventional method using population-average literature relaxation values. Healthy participants and participants with mutant
resultsSix healthy participants (four male; mean age, 37 years ± 11 [SD]) and nine participants with glioma (six male; mean age, 41 years ± 15; one with wild-type
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging. · full record | OpenQuestion